Literature DB >> 16393273

Effects of steroid treatment on lung CC chemokines, apoptosis and transepithelial cell clearance during development and resolution of allergic airway inflammation.

L Uller1, C M Lloyd, K Rydell-Törmänen, C G A Persson, J S Erjefält.   

Abstract

BACKGROUND: Steroid treatment of allergic eosinophilic airway diseases is considered to attenuate cell recruitment by inhibiting several chemokines and to cause eosinophil clearance through inducement of apoptosis of these cells. However, roles of these mechanisms in the actions of steroids in vivo have not been fully established. Also, as regards clearance of tissue eosinophils other mechanisms than apoptosis may operate in vivo.
OBJECTIVE: This study explores anti-inflammatory effects of steroids instituted during either development or resolution of airway allergic inflammation.
METHODS: Immunized mice were subjected to week-long daily allergen challenges (ovalbumin). Steroid treatment was instituted either amidst the challenges or exclusively post-allergen challenge. CC chemokines, goblet cell hyperplasia, occurrence of eosinophil apoptosis, and airway tissue as well as lumen eosinophilia were examined at different time-points.
RESULTS: Daily steroids instituted amid the allergen challenges non-selectively attenuated a range of chemokines, permitted egression of tissue eosinophils into airway lumen to increase, and reduced development of lung tissue eosinophilia. Steroid treatment instituted post-challenge selectively inhibited the CC-chemokine regulation upon activation, normal T cell expressed and secrted (RANTES), permitted continued egression of eosinophils into airway lumen, and resolved the tissue eosinophilia. Eosinophil apoptosis rarely occurred at development and resolution of the allergic eosinophilic inflammation whether the animals were steroid treated or not. However, anti-Fas monoclonal antibodies given to mice with established eosinophilia post-challenge produced apoptosis of the tissue eosinophils indicating that apoptotic eosinophils, if they occur, are well detectible in vivo.
CONCLUSION: Airway tissue eosinophils are likely eliminated through egression into airway lumen with little involvement of apoptosis and phagocytosis. Our data further suggest that therapeutic steroids may resolve airway inflammation by permitting clearance of tissue eosinophils through egression and inhibiting RANTES-dependent cell recruitment to lung tissues.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16393273      PMCID: PMC3389735          DOI: 10.1111/j.1365-2222.2006.02396.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  34 in total

Review 1.  Pharmacological manipulation of granulocyte apoptosis: potential therapeutic targets.

Authors:  C Ward; I Dransfield; E R Chilvers; C Haslett; A G Rossi
Journal:  Trends Pharmacol Sci       Date:  1999-12       Impact factor: 14.819

Review 2.  New aspects of degranulation and fates of airway mucosal eosinophils.

Authors:  J S Erjefält; C G Persson
Journal:  Am J Respir Crit Care Med       Date:  2000-06       Impact factor: 21.405

Review 3.  Asthma.

Authors:  W W Busse; R F Lemanske
Journal:  N Engl J Med       Date:  2001-02-01       Impact factor: 91.245

Review 4.  Chemokines in allergic lung inflammation.

Authors:  Clare Lloyd
Journal:  Immunology       Date:  2002-02       Impact factor: 7.397

5.  Exacerbations of Bronchitis: bronchial eosinophilia and gene expression for interleukin-4, interleukin-5, and eosinophil chemoattractants.

Authors:  J Zhu; Y S Qiu; S Majumdar; E Gamble; D Matin; G Turato; L M Fabbri; N Barnes; M Saetta; P K Jeffery
Journal:  Am J Respir Crit Care Med       Date:  2001-07-01       Impact factor: 21.405

6.  Effects of inhaled corticosteroid therapy on expression and DNA-binding activity of nuclear factor kappaB in asthma.

Authors:  L Hart; S Lim; I Adcock; P J Barnes; K F Chung
Journal:  Am J Respir Crit Care Med       Date:  2000-01       Impact factor: 21.405

7.  Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics.

Authors:  S Ying; Q Meng; K Zeibecoglou; D S Robinson; A Macfarlane; M Humbert; A B Kay
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

8.  Lung tissue eosinophils may be cleared through luminal entry rather than apoptosis: effects of steroid treatment.

Authors:  L Uller; C G Persson; L Källström; J S Erjefält
Journal:  Am J Respir Crit Care Med       Date:  2001-11-15       Impact factor: 21.405

9.  Effects of budesonide and formoterol on NF-kappaB, adhesion molecules, and cytokines in asthma.

Authors:  S J Wilson; A Wallin; G Della-Cioppa; T Sandström; S T Holgate
Journal:  Am J Respir Crit Care Med       Date:  2001-09-15       Impact factor: 21.405

10.  The effects of intranasal budesonide on allergen-induced production of interleukin-5 and eotaxin, airways, blood, and bone marrow eosinophilia, and eosinophil progenitor expansion in sensitized mice.

Authors:  Huahao Shen; Paul M O'Byrne; Russ Ellis; Jennifer Wattie; Chibing Tang; Mark D Inman
Journal:  Am J Respir Crit Care Med       Date:  2002-07-15       Impact factor: 21.405

View more
  10 in total

Review 1.  Resolution of leucocyte-mediated mucosal diseases. A novel in vivo paradigm for drug development.

Authors:  Carl Persson; Lena Uller
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  Resolution of cell-mediated airways diseases.

Authors:  Carl G Persson; Lena Uller
Journal:  Respir Res       Date:  2010-06-11

3.  Early phase resolution of mucosal eosinophilic inflammation in allergic rhinitis.

Authors:  Lena Uller; Cecilia Ahlström Emanuelsson; Morgan Andersson; Jonas S Erjefält; Lennart Greiff; Carl G Persson
Journal:  Respir Res       Date:  2010-05-09

4.  Steroid-resistant lymphatic remodeling in chronically inflamed mouse airways.

Authors:  Li-Chin Yao; Peter Baluk; Jennifer Feng; Donald M McDonald
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

Review 5.  Eosinophils in the pathogenesis of allergic airways disease.

Authors:  S G Trivedi; C M Lloyd
Journal:  Cell Mol Life Sci       Date:  2007-05       Impact factor: 9.261

6.  Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist.

Authors:  Monica Baiula; Antonino Spartà; Andrea Bedini; Gioia Carbonari; Claudio Bucolo; Keith W Ward; Jin-Zhong Zhang; Paolo Govoni; Santi Spampinato
Journal:  Mol Vis       Date:  2011-12-14       Impact factor: 2.367

7.  Activation of the stress axis and neurochemical alterations in specific brain areas by concentrated ambient particle exposure with concomitant allergic airway disease.

Authors:  Madhu P Sirivelu; Sheba M J MohanKumar; James G Wagner; Jack R Harkema; Puliyur S MohanKumar
Journal:  Environ Health Perspect       Date:  2006-06       Impact factor: 9.031

8.  Antagonism of the prostaglandin D2 receptor CRTH2 attenuates asthma pathology in mouse eosinophilic airway inflammation.

Authors:  Lena Uller; Jesper Mosolff Mathiesen; Lisa Alenmyr; Magnus Korsgren; Trond Ulven; Thomas Högberg; Gunnar Andersson; Carl G A Persson; Evi Kostenis
Journal:  Respir Res       Date:  2007-02-28

9.  Mapracorat, a selective glucocorticoid receptor agonist, causes apoptosis of eosinophils infiltrating the conjunctiva in late-phase experimental ocular allergy.

Authors:  Monica Baiula; Andrea Bedini; Jacopo Baldi; Megan E Cavet; Paolo Govoni; Santi Spampinato
Journal:  Drug Des Devel Ther       Date:  2014-06-10       Impact factor: 4.162

10.  Inhaled dsRNA and rhinovirus evoke neutrophilic exacerbation and lung expression of thymic stromal lymphopoietin in allergic mice with established experimental asthma.

Authors:  I Mahmutovic-Persson; H Akbarshahi; N W Bartlett; N Glanville; S L Johnston; A Brandelius; L Uller
Journal:  Allergy       Date:  2013-11-28       Impact factor: 13.146

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.